At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 60 target
Drug / intervention
ZG005 for Injection +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
In Brief
A Phase 2 clinical trial evaluating ZG005 for Injection and Gecacitinib Hydrochloride Tablets for Lymphoma. Currently recruiting, targeting 60 participants across 1 site.
Detailed Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20262027
First PostedMar 2025
Enrollment StartMay 2025
TodayJul 2026
Primary CompletionApr 2027
Study CompletionMay 2027
First PostedMar 19, 2025
Enrollment StartMay 16, 2025
Primary CompletionApr 1, 2027
Study CompletionMay 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.3 years agoPrimary completion in 9 months
Interventions
ZG005 for Injectionbiological
intravenous infusion
Gecacitinib Hydrochloride Tabletsdrug
Oral